Skip to main content

Advertisement

Table 5 Hazard ratio (HRs) and 95 % confidence intervals (CIs) for fractures in the tamoxifen users compared with non-users using the time-dependent model stratified by comorbidity

From: Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study

Comorbidity Tamoxifen user vs. non-user HR (95 % CI) p-value Interaction p
Hypertension    0.18
No 0.67 (0.53-0.85) 0.001  
Yes 0.55 (0.46-0.66) <0.0001  
Hyperlipidemia    0.97
No 0.60 (0.50-0.72) <0.0001  
Yes 0.58 (0.45-0.74) <0.0001  
Diabetes    0.56
No 0.62 (0.52-0.74) <0.0001  
Yes 0.54 (0.41-0.71) <0.0001  
PAD    0.58
No 0.59 (0.50-0.68) <0.0001  
Yes 0.73 (0.37-1.46) 0.38  
Stroke    0.32
No 0.59 (0.50-0.69) <0.0001  
Yes 0.68 (0.41-1.13) 0.14  
Osteoporosis    0.33
No 0.61 (0.51-0.73) <0.0001  
Yes 0.54 (0.40-0.72) <0.0001  
  1. PAD, peripheral artery disease
  2. Manually adjusted for monthly income, comorbidity and aromatase inhibitor use before the end point